Integra LifeSciences Holdings Corporation (IART)

Over the past six months, Integra LifeSciences' stock has experienced significant fluctuations, with a notable decrease in share price from April 7, 2025, to April 6, 2026. The stock closed at $9.33 on March 20, 2026, which was 7.24% above its 52-week low. A significant event impacting the stock was a $511 million goodwill impairment charge recorded in the second quarter of 2025, leading to a GAAP net loss. Recent news includes Integra LifeSciences unveiling new real-world evidence highlighting PriMatrix® utilization on April 7, 2026, reporting its fourth-quarter and full-year 2025 financial results and providing 2026 financial guidance on February 26, 2026, and completing the acquisition of Acclarent, Inc. for $280 million on April 2, 2026.

Information regarding specific demand seasonality for Integra LifeSciences Holdings Corp. products and services was not explicitly found. The company's focus on neurosurgery, reconstructive surgery, and advanced wound care suggests a generally consistent demand driven by medical necessity rather than strong seasonal fluctuations. The company's strategic moves to boost quality and compliance are aimed at meeting market demand, implying a steady underlying need for their products.

Integra LifeSciences Holdings Corporation, founded in 1989 and headquartered in Princeton, New Jersey, is a global medical technology company operating in the Medical Equipment, Supplies & Distribution sector and the Medical Devices industry. The company develops, manufactures, and markets medical technologies and products across two primary segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS segment offers technologies and instrumentation for specialties such as neurosurgery, neurocritical care, and otolaryngology, while the TT segment concentrates on complex wound surgery, surgical reconstruction, and peripheral nerve repair. In 2024, Integra acquired Acclarent, an ENT solutions player, further augmenting its CSS business.

Integra LifeSciences Holdings Corp. has a global commercial footprint, serving Europe, Asia Pacific, and the rest of the world, with key revenue from domestic sales in the United States. Its global commercial network includes clinical specialists, a direct global sales force, and strategic partnerships and distributors that cater to hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and healthcare providers. Outside the United States, Integra utilizes a combination of direct and indirect sales channels in international markets for certain product lines.

In the past year, Integra LifeSciences has focused on strengthening its operations and quality capabilities to enhance supply resilience and accelerate margin expansion. The company's reputation has been impacted by "quality, operational, and supply issues" which contributed to a significant goodwill impairment charge in Q2 2025. Despite these challenges, Integra LifeSciences continues to be recognized in the medical technology industry, ranking #59 on Medical Design and Outsourcing's list of largest medical technology companies in the world in 2023. The company also announced CEO changes on November 4, 2025, and board changes on February 29, 2026.

Integra LifeSciences Holdings Corporation's ownership is heavily weighted towards institutional investors, with 208 institutional owners and shareholders holding a total of 75,257,243 shares. Institutional investors hold between 84.78% and 93.34% of the shares. Major institutional shareholders include BlackRock, Inc., Rubric Capital Management LP, Vanguard Group Inc, Morgan Stanley. Insider ownership was reported at 3.3% as of April 2025, with recent insider activity showing more purchases than sales over the past year.